These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19138773)

  • 1. The multiple sclerosis severity score (MSSS) predicts disease severity over time.
    Pachner AR; Steiner I
    J Neurol Sci; 2009 Mar; 278(1-2):66-70. PubMed ID: 19138773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
    Roxburgh RH; Seaman SR; Masterman T; Hensiek AE; Sawcer SJ; Vukusic S; Achiti I; Confavreux C; Coustans M; le Page E; Edan G; McDonnell GV; Hawkins S; Trojano M; Liguori M; Cocco E; Marrosu MG; Tesser F; Leone MA; Weber A; Zipp F; Miterski B; Epplen JT; Oturai A; Sørensen PS; Celius EG; Lara NT; Montalban X; Villoslada P; Silva AM; Marta M; Leite I; Dubois B; Rubio J; Butzkueven H; Kilpatrick T; Mycko MP; Selmaj KW; Rio ME; Sá M; Salemi G; Savettieri G; Hillert J; Compston DA
    Neurology; 2005 Apr; 64(7):1144-51. PubMed ID: 15824338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
    Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
    Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
    J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis of the individual course of disease: the elements of time, heterogeneity and precision.
    Daumer M; Neuhaus A; Herbert J; Ebers G
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S50-5. PubMed ID: 20106349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.
    Baronica KB; Mlinac K; Ozretić D; Vladić A; Bognar SK
    Coll Antropol; 2011 Jan; 35 Suppl 1():11-6. PubMed ID: 21648305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between MRI parameters and the MS severity scale: a 12 year follow-up study.
    Minneboo A; Uitdehaag BM; Jongen P; Vrenken H; Knol Dl; van Walderveen MA; Polman CH; Castelijns JA; Barkhof F
    Mult Scler; 2009 May; 15(5):632-7. PubMed ID: 19389751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
    Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
    Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-dimensional-ratio measures of atrophy progression in multiple sclerosis as evaluated by longitudinal magnetic resonance imaging.
    Martola J; Stawiarz L; Fredrikson S; Hillert J; Bergström J; Flodmark O; Aspelin P; Wiberg MK
    Acta Radiol; 2009 Oct; 50(8):924-32. PubMed ID: 19639474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term effects of prolonged fasting on multiple sclerosis.
    Saadatnia M; Etemadifar M; Fatehi F; Ashtari F; Shaygannejad V; Chitsaz A; Maghzi AH
    Eur Neurol; 2009; 61(4):230-2. PubMed ID: 19176964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric Multiple Sclerosis Severity Score in a large US cohort.
    Santoro JD; Waltz M; Aaen G; Belman A; Benson L; Gorman M; Goyal MS; Graves JS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rensel M; Rodriguez M; Schreiner T; Tillema JM; Waubant E; Weinstock-Guttman B; Hurtubise BF; Roalstad S; Rose J; Casper TC; Chitnis T;
    Neurology; 2020 Sep; 95(13):e1844-e1853. PubMed ID: 32690790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-rated physical health predicts change in disability in multiple sclerosis.
    Drulovic J; Riise T; Nortvedt M; Pekmezovic T; Manigoda M
    Mult Scler; 2008 Aug; 14(7):999-1002. PubMed ID: 18505776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of associations between disability in multiple sclerosis, skin type, gender and ultraviolet radiation.
    Woolmore JA; Stone M; Pye EM; Partridge JM; Boggild M; Young C; Jones PW; Fryer AA; Hawkins CP; Strange RC
    Mult Scler; 2007 Apr; 13(3):369-75. PubMed ID: 17439906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis].
    Saiz A; Blanco Y; Berenguer J; Gómez-Choco M; Carreras E; Arbizu T; Graus F
    Neurologia; 2008 Sep; 23(7):405-7. PubMed ID: 18726717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of the individual course of disease--steps in developing a decision support tool for Multiple Sclerosis.
    Daumer M; Neuhaus A; Lederer C; Scholz M; Wolinsky JS; Heiderhoff M;
    BMC Med Inform Decis Mak; 2007 May; 7():11. PubMed ID: 17488517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of cerebrospinal fluid in multiple sclerosis.
    Siritho S; Freedman MS
    J Neurol Sci; 2009 Apr; 279(1-2):21-5. PubMed ID: 19181345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis.
    Benedetti B; Rovaris M; Rocca MA; Caputo D; Zaffaroni M; Capra R; Bertolotto A; Martinelli V; Comi G; Filippi M
    Mult Scler; 2009 Jul; 15(7):789-94. PubMed ID: 19465450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.